Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study

Işıkoğlu, Mete; Berkkanoğlu, Murat; Senturk, Z.; Özgür, Kemal

doi:10.1016/j.fertnstert.2006.11.170

Cited by 24 publications

(25 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is noteworthy that we compared two drugs with different preventive mechanisms; Albumin seems to have osmotic functions that draw extracellular fluid into the circulation and possesses transport functions, binding and inactivating the vasoactive intermediates responsible for the pathogenesis of OHSS, Our data and many of currently studies [5][6][7][8][9] support the suggestion that the intravenous albumin administration (20 gr in the day of oocyte retrieval) does not reduce the occurrence of severe OHSS. Our results showed that human albumin at this dose, hadn't any benefit effects on reduction the incidence of moderate OHSS too.…”

Section: Discussionsupporting

confidence: 62%

See 1 more Smart Citation

Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial

Tehraninejad

Hafezi

Arabipoor

et al. 2012

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 62%

“…Some studies suggested a role for albumin in the prevention of OHSS [2][3][4]. However, in several recent studies the effect of HA was similar to a placebo [5,6] and less than other preventive drugs [7][8][9]. A recent review article reported low evidence of benefit from i.v.…”

Section: Introductionmentioning

confidence: 99%

Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial

Tehraninejad

Hafezi

Arabipoor

et al. 2012

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Since then, further RCTs have evaluated the effectiveness of albumin infusion on the day of oocyte retrieval and consistently reported that this intervention is not a useful means of preventing the development of OHSS [18,19] . The effectiveness of albumin infusion appears to be questionable because the study by Bellver et al [18] was a larger-scaled trial than ever published.…”

Section: Introductionmentioning

confidence: 99%

Administration of Intravenous Albumin around the Time of Oocyte Retrieval Reduces Pregnancy Rate without Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Meta-Analysis

Jee

Suh

Kim

et al. 2010

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background/Aim: The aim of this meta-analysis was to evaluate whether IV albumin infusion around the time of oocyte retrieval prevents ovarian hyperstimulation syndrome (OHSS) and affects the pregnancy rate. Methods: A meta-analysis of data from 9 randomized controlled trials including 1,613 women at high risk for developing OHSS in in vitro fertilization cycles was performed. Results: The combined incidence of severe OHSS was 6.0% in the IV albumin group and 7.9% in saline or no treatment groups. These rates were statistically not different (RR = 0.80, 95% CI = 0.57–1.12). Treatment with IV albumin significantly lowered the pregnancy rates (RR = 0.85, 95% CI = 0.74–0.98). Conclusions: The combined data presented in this meta-analysis do not support a benefit for IV albumin around the time of oocyte retrieval in preventing OHSS and even showed a deleterious effect on the pregnancy rate.

show abstract

“…However, subsequent clinical trials have not shown any benefit in its use [31,32]. In one of these studies, a RCT that included 998 high-risk women [32], the administration of 40 g of human albumin immediately after the oocyte retrieval was compared with no treatment.…”

Section: Albumin Administrationmentioning

confidence: 99%

Ovarian hyperstimulation syndrome: pathophysiology and prevention

Nastri

Ferriani

Rocha

et al. 2010

J Assist Reprod Genet

194

157

View full text Add to dashboard Cite

Purpose To review and discuss the pathophysiology and prevention strategies for ovarian hyperstimulation syndrome (OHSS), which is a condition that may occur in up to 20% of the high risk women submitted to assisted reproductive technology cycles. Methods The English language literature on these topics were reviewed through PubMed and discussed with emphasis on recent data. Results The role of estradiol, luteinizing hormone, human chorionic gonadotropin (hCG), inflammatory mediators, the renin-angiotensin system and vascular endothelial growth factor is discussed in the pathophysiology of OHSS. In addition we consider the prevention strategies, including coasting, administration of albumin, renin-angiotensin system blockage, dopamine agonist administration, nonsteroidal anti-inflammatory administration, GnRH antagonist protocols, reducing hCG dosage, replacement of hCG and in vitro maturation of oocytes (IVM). Conclusions Among the many prevention strategies that have been discussed, the current evidence points to the replacement of hCG by GnRH agonists in antagonist cycles and the performance of IVM procedures as the safest approaches.

show abstract

Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study

Cited by 24 publications

References 26 publications

Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial

Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial

Administration of Intravenous Albumin around the Time of Oocyte Retrieval Reduces Pregnancy Rate without Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Meta-Analysis

Ovarian hyperstimulation syndrome: pathophysiology and prevention

Contact Info

Product

Resources

About